Nature of Disclosure: Regulatory filing pursuant to SEBI Listing Regulations 30 and 33, containing the outcome of the Board of Directors meeting held on August 03, 2026.

Board Meeting Details: The meeting commenced at 08:00 AM IST and concluded at 09:20 AM IST on August 03, 2026.

Approved Items:

1. Unaudited Financial Results: Approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026 (Q1 FY27). The results were reviewed by the Audit Committee and subjected to limited review by the statutory auditors, Agiwal & Associates, who issued an unmodified opinion.

2. Acquisition of Mehar Hospital-Zirakpur: Approved the acquisition of "Mehar Hospital-Zirakpur," owned and operated by Mehar Mediserve LLP (LLPIN: AAH-6659).

  • Transaction Value: Approximately ₹107 crores
  • Consideration: All-cash transaction for 100% stake
  • Target Business: Multi-super speciality hospital with 150+ beds in Zirakpur, Punjab
  • Target Financials: Turnover of ₹19.10 crores (unaudited) for FY 2025-26, ₹18.87 crores for FY 2024-25, and ₹17.52 crores for FY 2023-24
  • Expected Completion: December 03, 2026
  • Strategic Rationale: Part of growth strategy to maximize operational synergies and achieve economies of scale in high-potential markets. Not a related party transaction.

3. Variation in IPO Proceeds Utilization: Approved variation in the objects of the Initial Public Offer proceeds as stated in the Prospectus dated December 12, 2025, subject to approval of shareholders by way of Postal Ballot.

Financial Results - Standalone (₹ in millions, except per share data):

  • Quarter Ended June 30, 2026 (Q1 FY27):
  • Revenue from operations: ₹335.32
  • Other income: ₹46.68
  • Total Income: ₹382.00
  • Total Expenses: ₹364.89
  • Profit before tax: ₹17.11
  • Tax expense: ₹6.27
  • Profit after tax: ₹10.84
  • Other comprehensive loss: ₹(0.73)
  • Total comprehensive income: ₹10.11
  • Basic and Diluted EPS: ₹0.03
  • Comparative Figures:
  • Q1 FY26 (June 30, 2025): PAT ₹48.97 million, EPS ₹0.13
  • Q4 FY26 (March 31, 2026): PAT ₹86.06 million, EPS ₹0.20
  • Full Year FY26: PAT ₹366.16 million, EPS ₹0.92
  • Share Capital: Paid-up equity share capital remained unchanged at ₹863.86 million (face value ₹2 per share).

Financial Results - Consolidated (₹ in millions, except per share data):

  • Quarter Ended June 30, 2026 (Q1 FY27):
  • Revenue from operations: ₹4,757.09
  • Other income: ₹76.46
  • Total Income: ₹4,833.55
  • Total Expenses: ₹3,782.71
  • Profit before tax: ₹1,050.84
  • Tax expense: ₹164.91
  • Profit after tax: ₹885.93
  • Other comprehensive loss: ₹(5.81)
  • Total comprehensive income: ₹880.12
  • PAT attributable to owners: ₹825.07
  • Basic and Diluted EPS: ₹2.05
  • Comparative Figures:
  • Q1 FY26: PAT ₹655.06 million, EPS ₹1.70
  • Q4 FY26: PAT ₹767.78 million, EPS ₹1.78
  • Full Year FY26: PAT ₹2,735.57 million, EPS ₹6.87

Operational and Strategic Updates:

  • New Hospital Launch: Launched a 350-bed advanced multi-super specialty hospital at Panchkula on April 10, 2026, equipped with advanced diagnostics and modular operation theaters.
  • Capacity Expansion: Umkal Healthcare Private Limited (wholly-owned subsidiary) proposed expansion of its existing 225-bed Park Hospital in Palam Vihar, Gurugram, by adding 100 new beds to be branded as "Park Hospital Platinum." Expected completion by November 2026 at an approximate cost of ₹250 million, funded from internal accruals.
  • New Subsidiary: Park Medicentres and Institutions Private Limited incorporated a wholly-owned subsidiary, "Healplus Medical Services Private Limited" (CIN: U47721DC2026PTC471594) on May 20, 2026. No business operations commenced as of June 30, 2026.
  • Divestment: Aggarwal Hospital and Research Services Private Limited divested its entire 55% shareholding in Devina Derma Private Limited for ₹0.60 million on June 05, 2026.
  • Subsequent Event: Acquired 80% shareholding in V3 Healthcare Private Limited (operates "The Medicity Hospital - Rudrapur," Uttarakhand, 330 beds) on July 31, 2026, for approximately ₹1,770 million. Remaining 20% to be acquired by April 30, 2030. The hospital was launched on August 02, 2026.

IPO Proceeds Utilization (as of June 30, 2026):

  • Total IPO proceeds: ₹7,700.00 million
  • Amount utilized: ₹7,051.68 million
  • Unutilized balance: ₹648.32 million
  • Breakdown of Utilization:
  • Funding capex for new hospital by Park Medicity (NCR) Private Limited: ₹605.00 million allocated, ₹195.19 million utilized, ₹409.81 million unutilized
  • Funding medical equipment purchase: ₹274.59 million allocated, ₹36.08 million utilized, ₹238.51 million unutilized
  • Unidentified inorganic acquisitions and general corporate purposes: ₹2,453.18 million fully utilized
  • Issue expenses: ₹567.23 million fully utilized
  • The company stated there is no deviation in the utilization of proceeds from the objects stated in the offer document.

Investor Relations: During the quarter ended June 30, 2026, the company did not receive any investor complaints, and no complaints were pending resolution as of that date.

Regulatory References: Disclosure made under SEBI Listing Regulations 30 and 33, with reference to SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Availability of Documents: The financial results are available on the company's website (www.parkhospital.in) and on the websites of BSE Limited (www.bseindia.com) and National Stock Exchange of India Limited (www.nseindia.com).